Teacher Retirement System of Texas Has $2.02 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Teacher Retirement System of Texas lowered its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 38.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,568 shares of the medical equipment provider’s stock after selling 13,827 shares during the period. Teacher Retirement System of Texas’ holdings in Lantheus were worth $2,019,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Quest Partners LLC grew its holdings in shares of Lantheus by 27,685.7% in the 3rd quarter. Quest Partners LLC now owns 1,945 shares of the medical equipment provider’s stock worth $213,000 after purchasing an additional 1,938 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Lantheus by 16.6% in the 3rd quarter. PNC Financial Services Group Inc. now owns 9,021 shares of the medical equipment provider’s stock valued at $990,000 after buying an additional 1,286 shares during the last quarter. Cerity Partners LLC increased its stake in shares of Lantheus by 19.8% in the 3rd quarter. Cerity Partners LLC now owns 11,897 shares of the medical equipment provider’s stock valued at $1,306,000 after buying an additional 1,966 shares during the period. Glenmede Trust Co. NA acquired a new stake in shares of Lantheus in the 3rd quarter valued at $540,000. Finally, CreativeOne Wealth LLC raised its position in shares of Lantheus by 10.7% during the third quarter. CreativeOne Wealth LLC now owns 5,167 shares of the medical equipment provider’s stock worth $567,000 after acquiring an additional 499 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on the company. Truist Financial lifted their price objective on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. B. Riley lowered their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Insider Activity at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by company insiders.

Lantheus Stock Performance

LNTH opened at $97.04 on Friday. Lantheus Holdings, Inc. has a twelve month low of $58.16 and a twelve month high of $126.89. The firm has a market cap of $6.65 billion, a PE ratio of 16.15 and a beta of 0.38. The firm’s fifty day moving average is $93.12 and its two-hundred day moving average is $96.47.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.